dc.contributor.author |
Takuva, Simbarashe G.
|
|
dc.contributor.author |
Nabyoma, J.M.
|
|
dc.contributor.author |
Dawood, H.
|
|
dc.contributor.author |
Black, A.
|
|
dc.contributor.author |
Maartens, G.
|
|
dc.contributor.author |
Parrish, Andrew
|
|
dc.contributor.author |
Leong, T.D.
|
|
dc.date.accessioned |
2020-06-02T09:02:56Z |
|
dc.date.available |
2020-06-02T09:02:56Z |
|
dc.date.issued |
2019-04 |
|
dc.description.abstract |
Co-trimoxazole (fixed-dose trimethoprim-sulfamethoxazole) is a broad-spectrum antibiotic used to prevent
opportunistic infections in patients with HIV infection. Primary
prophylaxis with co-trimoxazole has been shown to decrease
hospitalisation, morbidity and mortality among people living with
HIV, primarily by decreasing rates of malaria, pneumonia, diarrhoea,
Pneumocystis pneumonia, toxoplasmosis and severe bacterial
infections.Co-trimoxazole is inexpensive and widely available. In
standard adult treatment guidelines and essential medicine lists in
South Africa (SA), the current recommendation is that co-trimoxazole
should be provided for HIV-infected patients with a CD4+ count
˂200 cells/µL, HIV/tuberculosis (TB) co-infection and/or advanced
HIV disease (World Health Organization (WHO) stage 3 or 4). |
en_ZA |
dc.description.department |
School of Health Systems and Public Health (SHSPH) |
en_ZA |
dc.description.uri |
http://www.samj.org.za |
en_ZA |
dc.identifier.citation |
Takuva, S., Nabyoma, J.M., Dawood, H. et al. 2019,'Eligibility for co-trimoxazole prophylaxis among adult HIV-infected patients in South Africa', South African Medical Journal, vol. 109, no. 4, pp. 198-199. |
en_ZA |
dc.identifier.issn |
2078-5135 (online) |
|
dc.identifier.issn |
0256-9574 (print) |
|
dc.identifier.other |
10.7196/SAMJ.2019.v109i4.13877 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/74823 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
Health and Medical Publishing Group |
en_ZA |
dc.rights |
© 2019, South African Medical Association. This article is licensed under a Creative Commons Attribution-NonCommercial Works License (CC BY-NC 3.0). |
en_ZA |
dc.subject |
AIDS-related opportunistic infections |
en_ZA |
dc.subject |
CD4 Lymphocyte count |
en_ZA |
dc.subject |
Human immunodeficiency virus (HIV) |
en_ZA |
dc.subject |
Drug combination |
en_ZA |
dc.subject |
Adult |
en_ZA |
dc.subject |
South Africa (SA) |
en_ZA |
dc.title |
Eligibility for co-trimoxazole prophylaxis among adult HIV-infected patients in South Africa |
en_ZA |
dc.type |
Article |
en_ZA |